![Gideon Gross](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profil
Gideon Gross is the founder of ImmPACT-Bio Ltd.
He is also the founder of GentiBio, Inc.
Postes actifs de Gideon Gross
Sociétés | Poste | Début |
---|---|---|
GentiBio, Inc.
![]() GentiBio, Inc. BiotechnologyHealth Technology GentiBio, Inc. engages in the development of engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory, and allergic diseases. The company was founded by Adel Nada, David Rawlings, Jane H. Buckner, and Gideon Gross and is headquartered in Seattle, WA. | Fondateur | - |
Anciens postes connus de Gideon Gross
Sociétés | Poste | Fin |
---|---|---|
ImmPACT-Bio Ltd.
![]() ImmPACT-Bio Ltd. BiotechnologyHealth Technology ImmPACT-Bio Ltd. develops therapies to treat cancer. Its chimeric antigen receptor T-cell (CAR-T) therapy addresses the need to differentiate cancerous from non-cancerous tissues. The company was founded by Gideon Gross in April 2017 and is headquartered in Nes Ziona, Israel. | Fondateur | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 2 |
---|---|
ImmPACT-Bio Ltd.
![]() ImmPACT-Bio Ltd. BiotechnologyHealth Technology ImmPACT-Bio Ltd. develops therapies to treat cancer. Its chimeric antigen receptor T-cell (CAR-T) therapy addresses the need to differentiate cancerous from non-cancerous tissues. The company was founded by Gideon Gross in April 2017 and is headquartered in Nes Ziona, Israel. | Health Technology |
GentiBio, Inc.
![]() GentiBio, Inc. BiotechnologyHealth Technology GentiBio, Inc. engages in the development of engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory, and allergic diseases. The company was founded by Adel Nada, David Rawlings, Jane H. Buckner, and Gideon Gross and is headquartered in Seattle, WA. | Health Technology |